Payment overview · 2025
General Payments
$528.02
26 reported records · 11 companies
Healthcare provider profile · identity verified
Fred Brandon Sammons, DO
Allopathic & Osteopathic Physicians|Internal Medicine · KNOXVILLE, TN · NPI 1114338647
Verified facts
What the public records show
CMS Open Payments records show Fred Brandon Sammons, DO received $528.02 in general payments during 2025 across 26 reported records.
PFIZER INC. accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $99.22 | 18.8% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $92.04 | 17.4% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $79.83 | 15.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $65.20 | 12.3% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $55.15 | 10.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $44.75 | 8.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.36 | 5.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.19 | 3.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.89 | 3.0% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $13.93 | 2.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.46 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $528.02 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $99.22 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $99.22 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $79.83 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $67.49 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $67.49 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $55.15 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $45.63 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $44.75 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.36 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.55 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 195 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 79 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
183 | 49 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
79 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
72 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
195 | 59 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 985 | 268 |
| Atorvastatin Calcium | Atorvastatin Calcium | 895 | 262 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 875 | 271 |
| Amlodipine Besylate | Amlodipine Besylate | 654 | 200 |
| Lisinopril | Lisinopril | 575 | 167 |
| Losartan Potassium | Losartan Potassium | 541 | 166 |
| Pantoprazole Sodium | Pantoprazole Sodium | 418 | 126 |
| Omeprazole | Omeprazole | 396 | 123 |
| Simvastatin | Simvastatin | 330 | 94 |
| Tamsulosin Hcl | Tamsulosin Hcl | 317 | 104 |
| Metoprolol Succinate | Metoprolol Succinate | 306 | 93 |
| Gabapentin | Gabapentin | 258 | 78 |
| Allopurinol | Allopurinol | 237 | 66 |
| Meloxicam | Meloxicam | 224 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 211 | 65 |
| Sertraline Hcl | Sertraline Hcl | 208 | 67 |
| Metformin Hcl Er | Metformin Hcl | 204 | 67 |
| Alendronate Sodium | Alendronate Sodium | 202 | 60 |
| Montelukast Sodium | Montelukast Sodium | 201 | 61 |
| Eliquis | Apixaban | 195 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 192 | 60 |
| Alprazolam | Alprazolam | 188 | 49 |
| Synthroid | Levothyroxine Sodium | 183 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 179 | 65 |
| Trazodone Hcl | Trazodone Hcl | 167 | 52 |
| Metformin Hcl | Metformin Hcl | 165 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 157 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 151 | 45 |
| Irbesartan | Irbesartan | 143 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 141 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 135 | 37 |
| Ezetimibe | Ezetimibe | 133 | 41 |
| Finasteride | Finasteride | 131 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 129 | 39 |
| Lorazepam | Lorazepam | 116 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 32 |
| Furosemide | Furosemide | 95 | 36 |
| Carvedilol | Carvedilol | 94 | 34 |
| Tramadol Hcl | Tramadol Hcl | 94 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 92 | 24 |
| Potassium Chloride | Potassium Chloride | 88 | 35 |
| Atenolol | Atenolol | 87 | 23 |
| Famotidine | Famotidine | 87 | 34 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 86 | 28 |
| Buspirone Hcl | Buspirone Hcl | 85 | 26 |
| Spironolactone | Spironolactone | 85 | 25 |
| Celecoxib | Celecoxib | 82 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 81 | 22 |
| Jardiance | Empagliflozin | 79 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 21 |
| Xarelto | Rivaroxaban | 75 | 23 |
| Ozempic | Semaglutide | 74 | 21 |
| Bupropion Xl | Bupropion Hcl | 73 | 26 |
| Mounjaro | Tirzepatide | 72 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 43 |
| Estradiol | Estradiol | 67 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 20 |
| Fenofibrate | Fenofibrate | 66 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 64 | 22 |
| Clonazepam | Clonazepam | 62 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 61 | 17 |
| Valacyclovir | Valacyclovir Hcl | 60 | 28 |
| Benazepril Hcl | Benazepril Hcl | 59 | 17 |
| Prednisone | Prednisone | 57 | 32 |
| Azithromycin | Azithromycin | 56 | 49 |
| Ipratropium Bromide | Ipratropium Bromide | 54 | 14 |
| Warfarin Sodium | Warfarin Sodium | 53 | 15 |
| Ramipril | Ramipril | 52 | 15 |
| Pregabalin | Pregabalin | 51 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 23 |
| Lovastatin | Lovastatin | 49 | 12 |
| Propranolol Hcl | Propranolol Hcl | 49 | 13 |
| Azelastine Hcl | Azelastine Hcl | 48 | 19 |
| Glipizide Er | Glipizide | 47 | 13 |
| Nifedipine Er | Nifedipine | 47 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 43 | 12 |
| Temazepam | Temazepam | 42 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 13 |
| Lansoprazole | Lansoprazole | 40 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 30 |
| Chlorthalidone | Chlorthalidone | 39 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 12 |
| Repatha Sureclick | Evolocumab | 39 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | 11 |
| Memantine Hcl | Memantine Hcl | 35 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 35 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 34 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 33 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Cefdinir | Cefdinir | 32 | 28 |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | 11 |
| Methylprednisolone | Methylprednisolone | 28 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 23 |
| Methocarbamol | Methocarbamol | 27 | 12 |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 27 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 27 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 24 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 22 |
| Ibuprofen | Ibuprofen | 24 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 22 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 18 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 17 | 17 |
| Cephalexin | Cephalexin | 17 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 16 |
| Potassium Citrate Er | Potassium Citrate | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Eplerenone | Eplerenone | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $528.02 · 26 records | PFIZER INC. | ACCRUFER, AREXVY, ELIQUIS, GEMTESA, JARDIANCE, LEQVIO, Leqembi, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, SHINGRIX, VRAYLAR, Wegovy, ZEPBOUND, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error